US Stocks Movement | AstraZeneca (AZN.US) rises over 2% as Goldman Sachs is bullish, raising price target to $99

According to Jinse Finance APP, on Wednesday, AstraZeneca (AZN.US) rose more than 2%, closing at $81.99. Recently, Goldman Sachs released a research report stating that AstraZeneca announced positive results for Baxdrostat in the Phase III BaxHTN clinical trial at the 2025 European Society of Cardiology (ESC) annual meeting. Baxdrostat demonstrated strong efficacy in treating hypertension during the clinical trial and is expected to bring AstraZeneca sales opportunities worth several billions of dollars. Goldman Sachs has given AstraZeneca a "Buy" rating, with a 12-month target price of $99. This target price represents an upside of about 23% compared to the stock's closing price of $80.19 on Tuesday.

According to the information, Baxdrostat is a highly selective aldosterone synthase inhibitor (ASI) that targets one of the hormones responsible for increased blood pressure and elevated cardiovascular and renal risks. Currently, the drug is undergoing clinical trials worldwide, with more than 20,000 patients enrolled. The trials include monotherapy for hypertension and primary aldosteronism, combination therapy with dapagliflozin for chronic kidney disease and hypertension, as well as prevention of heart failure in hypertensive patients. It is reported that Baxdrostat is expected to be approved in the US and Europe in the first half of 2026, becoming the world's first marketed aldosterone synthase inhibitor (ASI) antihypertensive drug.